نتایج جستجو برای: asymmetric dimethylarginine

تعداد نتایج: 66105  

Journal: :Journal of the American College of Cardiology 2005
Thomas Thum Dimitrios Tsikas Sylvia Stein Maximilian Schultheiss Martin Eigenthaler Stefan D Anker Philip A Poole-Wilson Georg Ertl Johann Bauersachs

OBJECTIVES We tested the hypothesis that asymmetric dimethylarginine (ADMA) may be an endogenous inhibitor of endothelial progenitor cells (EPCs). BACKGROUND Endothelial progenitor cells play a pivotal role in regeneration of injured endothelium, thereby limiting the formation of atherosclerotic lesions. Reduced numbers of EPCs may affect progression of coronary artery disease. Regulation of ...

Journal: :Arteriosclerosis, thrombosis, and vascular biology 2012
Ben Caplin James Leiper

The asymmetric methylarginines inhibit nitric oxide synthesis in vivo by competing with L-arginine at the active site of nitric oxide synthase. High circulating levels of asymmetric dimethylarginine predict adverse outcomes, specifically vascular events but there is now increasing experimental and epidemiological evidence that these molecules, and the enzymes that regulate this pathway, play a ...

Journal: :Journal of the American College of Cardiology 2007
Hakuoh Konishi Karsten Sydow John P Cooke

OBJECTIVES We sought to determine if a reduction in asymmetric dimethylarginine (ADMA) enhances endothelial regeneration. BACKGROUND Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase (NOS). Increased plasma levels of ADMA are associated with endothelial vasodilator dysfunction in patients with vascular disease or risk factors. Asymmetric dimethylarginine is elimi...

Journal: :FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005
Soni Pullamsetti Ladislau Kiss Hossein Ardeschir Ghofrani Robert Voswinckel Peter Haredza Walter Klepetko Clemens Aigner Ludger Fink Jai Prakash Muyal Norbert Weissmann Friedrich Grimminger Werner Seeger Ralph Theo Schermuly

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS) and has been implicated in endothelial dysfunction. ADMA is metabolized by the enzyme dimethylarginine dimethylaminohydrolase (DDAH), with DDAH2 representing the predominant endothelial DDAH isoform. Symmetric dimethylarginine (SDMA), also originating from arginine methylation by protein arginine methyl...

2013
Thorsten Brenner Thomas H. Fleming David Spranz Peter Schemmer Thomas Bruckner Florian Uhle Eike O. Martin Markus A. Weigand Stefan Hofer

Recent investigations have indicated that reactive metabolites and AGE-RAGE-mediated inflammation might play an important role in the pathogenesis of ischemia-reperfusion injury in liver transplantation. In this observational clinical study, 150 patients were enrolled following liver transplantation from deceased donors. The occurrence of short-term complications within 10 days of transplantati...

Journal: :Circulation 2004
Vinod Achan

Asymmetric Dimethylarginine To the Editor: Kielstein et al1 describe the effects of the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine (ADMA), in humans in vivo but do not make reference to two previous human studies.2,3 In the original paper describing the presence of ADMA in human plasma and its accumulation in chronic renal failure, Vallance et al2 also described the...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید